Camp4 Therapeutics Corp (CAMP) CEO buys 6,551 shares in placement
Rhea-AI Filing Summary
Camp4 Therapeutics Corp director and Chief Executive Officer Josh Mandel-Brehm purchased 6,551 shares of common stock on August 3, 2026, at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement dated September 9, 2025, as amended August 3, 2026. Following this purchase, he directly owned 284,968 shares of Camp4 common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 6,551 shares
Net Buy
1 txn
Insider
Mandel-Brehm Josh
Role
Chief Executive Officer
Bought
6,551 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 6,551 | $1.65 | $11K |
Holdings After Transaction:
Common Stock — 284,968 shares (Direct)
Footnotes (1)
- F1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Key Figures
Shares purchased: 6,551 shares
Purchase price: $1.65 per share
Post-transaction holdings: 284,968 shares
+1 more
4 metrics
Shares purchased
6,551 shares
Common Stock acquired on August 3, 2026
Purchase price
$1.65 per share
Price paid in second closing of a private placement
Post-transaction holdings
284,968 shares
Common Stock directly owned after August 3, 2026 purchase
Reported buy transactions
1 transaction; 6,551 shares
Net-buy summary for this Form 4 filing
Key Terms
private placement, Securities Purchase Agreement, institutional investors
3 terms
private placement financial
"acquired shares in the second closing of a private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
institutional investors financial
"by and among the Issuer and certain institutional investors and certain directors"
Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider buying did Camp4 Therapeutics (CAMP) report in this Form 4?
Camp4 reported that CEO and director Josh Mandel-Brehm purchased 6,551 common shares on August 3, 2026, at $1.65 per share. The acquisition occurred in the second closing of a private placement under a Securities Purchase Agreement with the company.
Who is the insider involved in the latest CAMP Form 4 filing and what is his role?
The insider is Josh Mandel-Brehm, who serves as both a director and the Chief Executive Officer of Camp4 Therapeutics Corp (CAMP). He reported acquiring additional Camp4 common stock through a private placement on August 3, 2026.
Was the CAMP insider purchase made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 trading plan checkbox was not marked, and the footnote describes the transaction as part of a negotiated private placement, rather than trades executed under a pre-arranged 10b5-1 trading plan.
What type of security did the Camp4 (CAMP) insider acquire in this transaction?
Josh Mandel-Brehm acquired Common Stock of Camp4 Therapeutics Corp (CAMP). The filing reports a single non-derivative transaction in which he bought 6,551 shares of common stock in a private placement at a price of $1.65 per share.